Soft opening seen for Sensex, Nifty; L&T, Lupin, BHEL, PNB, TVS Motor shares in focus
The BSE Sensex and the NSE Nifty are expected to open flat to lower on Friday, following muted trends on SGX Nifty.
lupin
January 2022
December 2021
October 2021
March 2021
February 2021
November 2020
September 2019
August 2018
November 2017
Sensex, Nifty to open lower; HDFC Bank, Maruti, HCL Tech, Lupin, Sun Pharma in focus
The BSE Sensex and the NSE Nifty are poised to start the week on the back foot, tracking mixed global cues and negative trading at SGX Nifty.
Soft opening seen for Sensex, Nifty; RBL Bank, HP Adhesives, RIL, Lupin in focus
The BSE Sensex and the NSE Nifty are slated for a subdued opening on Monday, following mixed cues from Asian peers as Omicron fears grip markets.
Quality issues remain for Indian pharma companies: USFDA
The problems faced by FDA’s investigators in India are similar to those around the world, US Food and Drug Administration spokesperson Jeremy Kahn tells Fortune India.
India’s tuberculosis endemic in the Covid-19 era
Like during the pandemic, we must work together to improve awareness and outcomes in diagnosis, prevention, treatment, and eventual elimination of TB from the country.
‘The most remarkable change has been Jio’
Netflix boss Reed Hastings on the Jio effect on data prices in India, his ‘no rules’ management philosophy, the India growth strategy, and more. A Fortune India exclusive.
Healthcare leaders shine in MPW 2020 list
Cipla’s Samina Hamied, Lupin’s Vinita Gupta biggest rank gainers from the sector.
The toughest period is behind us: Vinita Gupta
India’s third-largest generic drugmaker Lupin is focussing on building a pipeline of specialty drugs, while cutting costs and addressing regulatory concerns.
‘New complex generics to augur well for Lupin’
Vinita Gupta is confident that new complex generics, specialty drugs and manufacturing quality enhancement plan will augur well for the company
US business remains Sun Pharma’s weak spot
US sales have dropped to less than a third of overall revenue from nearly half five years ago and profits have taken a beating despite cost synergies after the acquisition of Ranbaxy Laboratories.
